Silence Therapeutics plc

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

SLN$19.75+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Shareholders' Equity

SILENCE THERAPEUTICSPLC

Consolidated statements of changes in SHAREHOLDERS' equity

(in thousands, except share data)

	Ordinary Shares
Note · Shares · Cost · Additional paid-in capital · Accumulated other comprehensive income · Accumulateddeficit · Total shareholders'equity
At January 1, 2024		118,846,966	$8,847	$455,765	$(10,725)		$(431,894)		$21,993
Net loss		-	-	-		(45,309)		(45,309)
Foreign currency translation adjustments (net of tax)		-	-	-	(1,055)		-		(1,055)
Recognition of share-based payments	20	-	-	16,307	-		-		16,307
Options exercised in the year	19/20	1,408,443	-	(3,158)	-		3,158		-
Proceeds from shares issued		21,418,665	1,441	140,646	-		-		142,087
At December 31, 2024		141,674,074	$10,288	$609,560	$(11,780)		$(474,045)		$134,023
Net loss		-	-	-		(88,612)		(88,612)
Foreign currency translation adjustments (net of tax)		-	-	-	8,804		-		8,804
Recognition of share-based payments	20	-	-	8,074	-		-		8,074
Options exercised in the year	19/20	27,774	-	(85)	-		85		-
Proceeds from shares issued		-	2	13	-		-		15
At December 31, 2025		141,701,848	$10,290	$617,562	$(2,976)		$(562,572)		$62,304

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.